Considering the presence of dopaminergic receptors in the lumbosacral spinal cord, we tested whether apomorphine could exert a proerectile effect by acting at the spinal level. Intracavernous (ICP) and blood pressures (BP) were measured in anesthetized rats. ICP rises were quanti®ed (duration, percentage of ICPmaximumameanBP (ICPmaxaBP 6 100), area under ICP curve (AUCaBP) and sum of AUCaBP after intravenous (i.v.) and intrathecal (i.t.) injections of apomorphine alone or in presence of i.t. oxytocin (10 ng). Both 10 and 30 m mg i.v. apomorphine dosings elicited erectile events evidenced by ICP rises. Upon the 30 m mg i.v. injection, duration of ICP rises were increased from 25 AE 10 to 69 AE 18 s (P`0.001), ICPmaxaBP 6 100 from 21 AE 3 to 50 AE 14% (P 0.001), AUCaBP from 3 AE 1 to 14 AE 6 s (P 0.002) and sum of AUCaBP from 5 AE 7 to 34 AE 35 s (P 0.021). Upon 30 m mg i.t. injections of apomorphine at the lumbosacral level, the number of ICP rises was increased from 0.2 AE 0.4 to 3.0 AE 1.5, ICPmaxaBP 6 100 from 16 AE 9 to 43 AE 12 and sum of AUCaBP from 1 AE 3 to 31 AE 15 s compared to vehicle injection (P`0.05 for all parameters). Injection of 30 m mg i.v. or i.t. apomorphine non-signi®cantly enhanced the number and amplitude of the ICP rises induced by 10 ng i.t. oxytocin. However, the enhancement of the amplitude of the ICP rises elicited by i.t. oxytocin was more pronounced with i.t. apomorphine than with i.v. apomorphine. These results suggest the existence of a spinal site of action for apomorphine which may (1) participate to generation of erection and (2) exerts a facilitator effect on erection of supraspinal origin.
Introduction
Subcutaneous delivery of apomorphine, a D1aD2 dopamine receptor agonist, induces penile erection in animals and humans. 1, 2 Apomorphine formulated in sub-lingual, slow release tablets has appeared as a promising pharmacological treatment for erectile dysfunction of various origins. 3, 4 The proerectile activity of apomorphine is caused by stimulation of supraspinal central dopaminergic receptors and, in this view, the paraventricular nucleus of the hypothalamus (PVN) has been identi®ed as a key target. 5, 6 Cytological data suggest that apomorphine may also act at the spinal level. Immunocytochemical studies revealed that dopaminergic (DA) ®bers and terminals exist in virtually all laminae throughout the spinal cord. 7, 8 Furthermore, studies using ligand binding techniques have shown the presence of D1 and D2 receptors in the spinal cord. 9 In male rats, D2 receptors identi®ed with immunochemistry and in situ hybridization have been located in the parasympathetic nucleus of the lumbosacral spinal cord, which contains the cellular bodies of the proerectile autonomic neurons innervating the penis. 10, 11 D2 receptors have also been found to be particularly abundant in the dorsomedian and the dorsolateral nucleus which innervate bulbospongiosus and ischiocavernosus striated muscles involved in penile rigidity in the rat. 10 The implication of spinal DA receptors in the control of penile erection have been little explored. In conscious rats, re¯exive erections are depressed by peripheral injection of the non-speci®c dopaminergic agonist RDS-127 in normal and spinalized rats, and by intrathecal (i.t.) injection of apomorphine at the lumbosacral level. 12, 13 However, the hypothesis of a spinal site of action for the inducer proerectile effect of apomorphine has never been tested.
The aim of the present study was to assess whether apomorphine could induce erectile events measured by ICP rises of the intracavernous pressure when delivered at the lumbosacral level of the spinal cord in the anesthetized rat. The effects of intravenous (i.v.) and i.t. apomorphine injections were also compared in combination with i.t. oxytocin injections, which induce erection by mimicking supraspinal command. 14 
Materials and methods

Animal preparation
Sprague-Dawley rats (Charles-River, France), weighing 200 ± 250 g, were used in this study. Rats were anesthetized by intraperitoneal injection of urethane (1.2 gakg) and placed on a homeothermic blanket to maintain their temperature at 37 C during the experiment. A catheter was inserted into the left carotid artery for blood pressure (BP) monitoring and in the jugular vein for i.v. injections.
For i.t. injections, a catheter was inserted through the atlanto-occipital membrane and directed caudally. Correct implantation of the caudal tip of the catheter at the L4-L6 spinal level was checked by complete laminectomy of the spinal cord after the animal was killed. Previous experiments with dyed solutions have demonstrated that in these conditions, the diffusion of the injected solution from the site of injection was restricted to the neighbouring spinal metamers (data not shown).
For intracavernous pressure (ICP) monitoring, the penis was denuded of skin and a 25-gauge needle connected to a catheter was inserted into one corpus cavernosum. Arterial and cavernosal catheters were ®lled with heparinized saline (25 UIaml) and connected to pressure transducers (EM 750, Elcomatic, Glasgow, UK). Pressure signals were ampli®ed (Bionic Instruments, Nozay, France), digitized (Labmaster DMA, Scienti®c solutions, Solon, OH) and converted to millimeters of mercury (mm Hg) after calibration (Axotape V2, Axon Instruments, Foster city, CA). A stimulation of the cavernous nerve (30 s overall duration, 6 V, 10 Hz, 1 ms pulse) was performed at the end of the experiment to elicit an increase of ICP in order to certify the correct implantation of the intracavernosal catheter. 15 
Experimental protocol
Drugs were purchased from Sigma (Saint-QuentinFallavier, France). Apomorphine was prepared in saline supplemented with 0.05% ascorbic acid. Oxytocin (1 ngaml) was prepared in saline. Accordingly, vehicle refers to saline with ascorbic acid or saline. Experimental groups were constituted of 10 rats.
The beginning of each experiment consisted in 15 min recording in basal condition, after which the ®rst drug injection (i.t. andaor i.v.) was performed.
Rats in which diastolic blood pressure was inferior to 40 mm Hg during this time were excluded.
To study the effects of apomorphine injected i.v., two groups of rats received vehicle and 15 min later, either 10 mg (equivalent to 40 ± 50 mgakg) or 30 mg (120 ± 150 mgakg) i.v. apomorphine. The spinal effects of apomorphine were analysed in another group, in which cumulative injections (15 min delay between each) consisted in vehicle, 3, 10, 30 and 100 mg of apomorphine (10 ml for each injection, each followed by a¯ush of 10 ml saline) were performed every 15 min. Recording of ICP and BP lasted 15 min after the last injection.
Combination of i.t. apomorphine and i.t. oxytocin was studied in three groups. Ten ng of oxytocin were injected i.t., immediately followed by 10 mg or 30 mg of apomorphine or the same volume of vehicle (10 ml saline). 14 In two other groups, the 10 ng i.t. injection of oxytocin was immediately followed by i.v. delivery of 30 mg apomorphine or by the corresponding volume of vehicle (20 ml). In presence of oxytocin, recording of ICP and BP lasted 30 min after the last injection.
Quanti®cation of ICP rises
BP and ICP tracings were analysed retrospectively using software designed in our laboratory. Only ICP rises with a maximal value superior to the sum of the average 3 standard deviation of the ICP recorded during 15 min before the injection of drug or vehicle were quanti®ed. ICPmaxaBP 6 100 corresponded to the percentage of the ratio:maximal value reached by ICP during the rise (mmHg)amean BP (mmHg) for the duration of the ICP rise. The area under the curve of ICP rise divided by the mean BP, termed AUCaBP (s) and the sum of the AUCaBP (s) of all the ICP rises, which represents an index of overall erectile activity, were also calculated for each rat (see Figure 1 for illustration). All parameters were averaged per rat, except the sum of Spinal proerectile effect of apomorphine F Giuliano et al AUCaBP, and then per treatment. Rats who did not display any ICP rise (non-responding rats) during the recording were attributed the value 0 for the sum of AUCaBP and number of ICP rises. For nonresponding rats, ICPmaxaBP 6 100 and AUCaBP were considered as missing data for the statistical analysis.
Depending on the experiments, ICPmaxaBP 6 100 and AUCaBP were compared using t-test or one way ANOVA followed by multiple comparisons vs control group. The corresponding tests with repeated measures were used to compare the number of ICP rises and sum of AUCaBP when successive injections were performed in the same rat. All tests were conducted using SigmaStat 1 software, version 2.03 (SPSS, Erkrath, Germany). Differences were considered signi®cant when P`0.05.
Results
It is noteworthy that ICP rises were observed after vehicle injection, either i.t. or i.v. Such ICP rises are often referred as`spontaneous ICP rises', because they re¯ect the erectile activity observed in anesthetized rats in any recording conditions and are not related to saline or saline with ascorbic acid i.t. or i.v. injections.
Apomorphine i.v. did not signi®cantly increase the number of ICP rises compared to previous vehicle injections in the same rats (from 0.8 AE 0.8 to 1.5 AE 1.0 for 10 mg; from 1.4 AE 1.7 to 2.4 AE 2.0 for 30 mg). Conversely, the shape of the ICP rises after i.v. delivery of apomorphine was signi®cantly different compared to the ones observed after vehicle injection. Analysis with t-test revealed that the mean duration of the ICP rises (10 mg, P 0.006; 30 mg, P`0.001) and mean ICPmaxaBP 6 100 (10 mg, P 0.027; 30 mg, P 0.001) were signi®cantly increased by i.v. apomorphine (Figure 2A and B) when compared to vehicle injection. The increase of the ICPmaxaBP 6 100 (135%) and duration (178%) were more important for the 30 mg dosing than for the 10 mg dosing (Figure 2A and B) . These augmentations are re¯ected in an increase of the mean AUCaBP of the ICP rises for both doses, which was only signi®cant for the 30 mg apomorphine injection (440% of the value of the control group, P 0.002, ttest, Figure 2C ). The sum of AUCaBP was signi®-cantly increased by the i.v. injection of apomorphine at the 10 mg and 30 mg dosing compared to the vehicle i.v. injection (P 0.026 and P 0.023 respectively, paired t-test, Figure 2D ).
On average, only 0.2 AE 0.4 ICP rises were observed after i.t. injections of vehicle. In contrast, apomorphine delivered i.t. at the lumbosacral level elicited the occurence of ICP rises (3.0 AE 1.5 ICP rises after the 30 mg apomorphine injection; see Figure 3 for an example of original recording). The number of ICP rises followed a bell-shaped curve upon the cumulative i.t. injections of increasing doses apomorphine ( Figure 4A ). The number of ICP rises was signi®cantly increased after the 30 mg injection compared to the vehicle injection (one way ANOVA with repeated measures, [F(9, 4) 5.72, P 0.001]; Dunnett's test versus vehicle injection P`0.05, Figure 4A ). The mean ICPmaxaBP 6 100 of the ICP rises was signi®cantly increased after the 10 mg and 30 mg injection of apomorphine i.t. compared to the vehicle injection (One way ANOVA, [F(4, 23) 4.28, P 0.01]; Dunnett's test versus vehicle injection, P`0.05 for both; Figure 4B ). The mean AUCaBP of the ICP rises was increased upon the cumulative i. Spinal proerectile effect of apomorphine F Giuliano et al phine compared to vehicle injection (P`0.05, Figure 4C ). Duration of ICP rises remained unaffected (not shown). Intrathecal injection of 10 ng oxytocin alone consistently elicited the occurrence of ICP rises (overall 17 rats out of 20 displayed more than six ICP rises with ICPmaxaBP 6 100 greater than 40% during the 30 min post-injection period, Table 1 ). The combination of i.t. or i.v. injections of apomorphine with i.t. injections of oxytocin did not induce signi®cant variations of the number and shape of the ICP rises induced by oxytocin alone (Table 1) . However, i.t. injection of 30 mg apomorphine and 10 ng oxytocin increased ICPmaxaBP 6 100, AUCaBP and sum of AUCaBP by 88%, 136% and 75%, respectively compared to the injection of oxytocin alone (Table 1 ). In comparison, injection of 30 mg apomorphine i.v. and 10 ng oxytocin i.t. increased ICPmaxaBP 6 100 and AUCaBP by 36% and 29%, and decreased the sum of AUCaBP by 14%, compared to the injection of oxytocin alone (Table 1 ). The number in brackets represents the number of rats which display at least one ICP rise. One way ANOVA (apomorphine i.t. injections) or t-test (apomorphine i.v. injections) did not reveal signi®cant statistical effect of apomorphine injections, despite a strong tendency of 30 mg i.t. apomorphine to enhance the ICP rises induced by 10 ng i.t. oxytocin.
Spinal proerectile effect of apomorphine F Giuliano et al
Lastly, examination of the ICP recordings showed that upon apomorphine i.v. or i.t. injections, brief and sharp repeated increases of the ICP were superimposed to the ICP rises ( Figure 3B ). Such brief increases of the ICP were not present during the`spontaneous' ICP rises which occured upon vehicle injection.
Discussion
In these experiments in anesthetized rats, few ICP rises were observed after i.t. or i.v. vehicle injections. Apomorphine delivered i.v. at the dosing of 10 and 30 mg (®nal dosing 40 ± 50 and 120 ± 150 mgakg body weight) increased the occurrence of ICP rises compared to vehicle injection, and analysis of the tracings revealed a signi®cant increase of the amplitude and duration of ICP rises for both dosings. This result is in agreement with the wellknown central inducer effect of apomorphine originally described in the freely moving rat on the basis of behavioural responses and con®rmed later through recording of the intracavernous pressure. 1, 16 Such proerectile inducer activity has been explained through a speci®c activation of neurons in the PVN by apomorphine. 5, 6 However, the existence of dopaminergic projections from the A11 cell group to the spinal cord as well as an intrinsic dopaminergic innervation within the spinal cord raises the possibility of an additional direct action of apomorphine at this level. 17, 18 To investigate this statement, we directly delivered apomorphine at the spinal lumbosacral level with an intrathecal catheter, ie in the vicinity of the proerectile sacral parasympathetic nucleus. In preliminary experiments, we failed to modify the occurrence of ICP rises with i.t. injection of apomorphine in the range of 0.1 to 1 mg (not shown). Eventually, the number of the ICP rises and their amplitude measured by ICPmaxaBP 6 100 was signi®cantly increased after the i.t. injection of 30 mg apomorphine compared to an injection of vehicle. This strongly suggests that apomorphine exerts a spinal proerectile effect on the sacral parasympathetic nucleus, in accordance with the cytological data reporting a prominent expression of D2 receptors in neurons of the sacral parasympathetic area. 9, 10 The small, sharp increases of the ICP superimposed to the ICP rises ( Figure 3A ) observed after apomorphine injection are likely due to contractions of the ischiocavernosus muscles. 19 In physiological conditions, such contractions, which are only effective after engorgement by blood of the penis, enhances penile rigidity to allow ef®cient intromission. It is tempting to link the putative activity of the ischiocavernosus muscle observed after apomorphine i.v. or i.t. injections to the particular abundance of D2 receptors in the spinal motor nucleus of the ischiocavernosus muscles. 10 Thus, apomorphine may act at the spinal level on both autonomic (the SPN) and somatic (the spinal motor nucleus innervating the ischiocavernosus muscles) proerectile efferent pathways.
However, similar doses of i.t. apomorphine to the ones that elicit ICP rises in our model were shown to depress re¯exive erections induced by retraction of the preputial sheath in the conscious rat. 13 This suggests that apomorphine delivered at the lumbosacral level inhibits the afferent peripheral proerectile input during re¯exive erections. An effect of apomorphine on the sensitive afferens is supported by the presence of D2 receptors in the dorsal horn at the thoracolumbar level. 10 Whether apomorphine also inhibits the afferent input in the anesthetized rat, in addition to its proerectile effect on the efferent limb, remains a question to be answered.
We hypothesized that apomorphine at the spinal level could amplify proerectile inputs from supraspinal origin. In anesthetized rats, i.t. injections of oxytocin at the level of the sacral parasympathetic nucleus triggers the occurrence of erectile events and such injections likely mimic the physiological release of oxytocin through the paraventriculospinal pathway. 20, 21 We combined i.t. oxytocin delivery with apomorphine treatment. In this condition, the enhancement of the amplitude of oxytocin-induced ICP rises was much more pronounced when apomorphine was delivered i.t. at the lumbosacral level than when apomorphine was i.v. injected, although these differences were not signi®cant. The faint increase of the oxytocin-induced ICP rises after i.v. apomorphine suggests that the end result of i.v. apomorphine is the release of oxytocin at the parasympathetic level. 20, 21 Systemic apomorphine could not generate further pro-erectile effect, as exogenous i.t. oxytocin would already mimic the full activation of the pro-erectile descending pathway usually activated after i.v. apomorphine at the PVN level. On the other hand, apomorphine exogenously delivered at the lumbosacral level tends to trigger additional proerectile outputs to the ones generated by oxytocin. This suggests the existence of an intraspinal dopaminergic proerectile pathway which would not be activated after i.v. apomorphine delivery.
Taken together, our data suggest that apomorphine is involved in a multistep central control of penile erection including supraspinal and spinal sites of action. The physiological basis of the proerectile effects of apomorphine at the level of the sacral parasympathetic nucleus could be rep-resented by the activation of the hypothalamospinal dopaminergic pathway. 17 This dopaminergic pathway, possibly proerectile, deserves further investigation. Oxytocinergic and dopaminergic descending pathways may participate to the co-ordination of the somatic and autonomic component of the 
